Interleukin 18 gene polymorphisms predict risk and outcome of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND AIM: Inflammation has been extensively implicated in the pathogenesis of Alzheimer's disease (AD). Although there is evidence of a key role for cytokines in neuroinflammation processes, so far the proinflammatory cytokine interleukin (IL)-18 has not been associated with AD. The aim of this study was to investigate the impact of two polymorphisms of the human IL-18 gene promoter at positions -607 (C/A) and -137 (G/C) on both susceptibility to and progression of AD. RESULTS: The results revealed that the genotype distribution of the -607 (C/A) polymorphism was different between patients with AD and control subjects (chi2 = 7.99, df = 2, p = 0.0184). In particular, carriers of the CC genotype were at increased risk of developing AD (OR 2.33; 95% CI 1.29 to 4.22; p = 0.0052). The observed genotypes were in Hardy-Weinberg equilibrium, as for the -607 polymorphism, whereas the -137 polymorphism appeared in Hardy-Weinberg disequilibrium only in the patient group (p = 0.0061). Finally, in a 2 year follow-up study, the -137 CC genotype was strongly and specifically associated with a faster cognitive decline (F = 4.024; df = 4,192; p = 0.0037 for time by IL-18 -137 G/C group interaction) with no interaction effect with the apolipoprotein E epsilon4/non-epsilon4 allele presence. CONCLUSION: As IL-18 cytokine promoter gene polymorphisms have been previously described to have functional consequences on IL-18 expression, it is possible that individuals with a prevalent IL-18 gene variant have a dysregulated immune response, suggesting that IL-18 mediated immune mechanisms may play a crucial role in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Cummings, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040223 · Cited by 1,152
In-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054 · cited 1×
“[2, 3] Indeed, an early and consistent activation of microglia cells, the mononuclear phagocytes that participate in mechanisms of innate and adaptive immunity within the brain, have been demonstrated in the cerebral areas of neurodegeneration in AD patients.[4, 5] Although activated”
Microglia and inflammatory mechanisms in the clearance of amyloid β peptide
Rogers, J., Strohmeyer, R., Kovelowski, C. J., & Li, R. (2002) · Glia · doi:10.1002/glia.10153 · Cited by 381
Blasko, I., Stampfer‐Kountchev, M., Robatscher, P., Veerhuis, R., Eikelenboom, P., & Grubeck‐Loebenstein, B. (2004) · Aging Cell · doi:10.1111/j.1474-9728.2004.00101.x · Cited by 374 · cited 1×
“[6] Several and growing evidence suggests that chronic microglia-mediated immune response during Aβ deposition can prime an inflammatory destructive cascade and contribute to Aβ plaque formation, thus participating in AD aetiopathogenesis.[7] Cytokines, such as Interleukin (IL)-1, IL-6 and Tumour Necrosis Factor alpha…”
Griffin, W. S. T., & Mrak, R. E. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.72.2.233 · Cited by 248 · cited 14×
“However, no significant association among ApoE variant alleles and the studied IL-18 2607 and 2137 gene promoter polymorphisms was found in control subjects (x2 = 1.634; df = 2; p = 0.442 and Table 1 Frequency of genotypes of apolipoprotein E in control subjects and in patients with Alzheimer’s disease (total populati…”
InfluentialImmune reactive cells in senile plaques and cognitive decline in Alzheimer’s disease
Vehmas, A. K., Kawas, C. H., Stewart, W. F., & Troncoso, J. C. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00090-8 · Cited by 230 · cited 1×
“[2, 3] Indeed, an early and consistent activation of microglia cells, the mononuclear phagocytes that participate in mechanisms of innate and adaptive immunity within the brain, have been demonstrated in the cerebral areas of neurodegeneration in AD patients.[4, 5] Although activated”
Licastro, F., Grimaldi, L. M. E., Bonafè, M., Martina, C., Olivieri, F., Cavallone, L., Giovanietti, S., Masliah, E., & Franceschi, C. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00013-7 · Cited by 182 · cited 14×
“However, no significant association among ApoE variant alleles and the studied IL-18 2607 and 2137 gene promoter polymorphisms was found in control subjects (x2 = 1.634; df = 2; p = 0.442 and Table 1 Frequency of genotypes of apolipoprotein E in control subjects and in patients with Alzheimer’s disease (total populati…”
InfluentialMolecular Genetics of Late‐Onset Alzheimer's Disease
Kamboh, M. I. (2004) · Annals of Human Genetics · doi:10.1046/j.1529-8817.2004.00110.x · Cited by 170 · cited 1×
“From a genetic point of view, AD results to be influenced by multiple susceptibility loci, whose combinations contribute to the development of this disorder.[27] Accordingly, we have recently shown that genomic polymorphisms in GSTs, a family of enzymes that appear to be critical for the protection against oxidative s…”
Malaguarnera, L., Motta, M., Di Rosa, M., Anzaldi, M., & Malaguarnera, M. (2006) · Neuropathology · doi:10.1111/j.1440-1789.2006.00701.x · Cited by 93
Cited by
Neuroinflammation in Alzheimer's Disease and Mild Cognitive Impairment: A Field in Its Infancy
McGeer, E. G., & McGeer, P. L. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1219 · Cited by 346
ANISMAN, H., MERALI, Z., & HAYLEY, S. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.01.004 · Cited by 337
Alboni, S., Cervia, D., Sugama, S., & Conti, B. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-9 · Cited by 299
Oxidative stress and β-amyloid protein in Alzheimer’s disease
Cai, Z., Zhao, B., & Ratka, A. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-011-8155-9 · Cited by 279
“…are many theories about AD occur- rence and development, more and more data showed that the immune inflammatory reaction involving pro-inflammatory cytokines, such as IL-1, IL-6, and TNF-a, contribute to the progression of AD (Bossu et al. 2007; Bradt et al. 1998; Combs et al. 2000; Griffin 2006).”
BackgroundThe pathogenic role of the inflammasome in neurodegenerative diseases
Freeman, L. C., & Ting, J. P. ‐. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13217 · Cited by 276
Su, F., Bai, F., & Zhang, Z. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0055-4 · Cited by 221
The role of inflammasome in Alzheimer's disease
Liu, L., & Chan, C. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2013.12.007 · Cited by 196
The impact of obesity on neurodegenerative diseases.
Mazon, J. N., de Mello, A. H., Ferreira, G. K., & Rezin, G. T. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.06.002 · Cited by 185
Bossù, P., Ciaramella, A., Salani, F., Bizzoni, F., Varsi, E., Di Iulio, F., Giubilei, F., Gianni, W., Trequattrini, A., Moro, M. L., et al. (2008) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2007.10.001 · Cited by 116
“Finally, according to our previous observation about the influence of the IL-18 gene promoter polymorphisms on AD risk (Bossù et al., 2007), we observed that the increased production of PBMC-derived cytokine from AD patients, as compared to control subjects, was mainly attributable to subjects carrying the C/C variant…”
BackgroundMethodSelf-citation
Metadata
- Authors
- Bossu, P., Ciaramella, A., Moro, M. L., Bellincampi, L., Bernardini, S., Federici, G., Trequattrini, A., Macciardi, F., Spoletini, I., Di Iulio, F., Caltagirone, C., & Spalletta, G.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2007-08-01
- Volume
- 78
- Issue
- 8
- Pages
- 807-811
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2088580814
- Cited by
- 64
- References
- 10
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.